ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RDY Dr Reddys Laboratories Ltd

71.27
0.36 (0.51%)
Last Updated: 15:28:22
Delayed by 15 minutes

Period:

Draw Mode:

Volume 75,890
Bid Price
Ask Price
News -
Day High 71.30

Low
53.12

52 Week Range

High
77.72

Day Low 70.59
Company Name Stock Ticker Symbol Market Type
Dr Reddys Laboratories Ltd RDY NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.36 0.51% 71.27 15:28:22
Open Price Low Price High Price Close Price Prev Close
70.90 70.59 71.30 70.91
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,567 75,890 $ 71.07 $ 5,393,621 - 53.12 - 77.72
Last Trade Time Type Quantity Stock Price Currency
15:28:32 8 $ 71.245 USD

Dr Reddys Laboratories Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
0 166.53M - 252.99B 45.07B - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Dr Reddys Laboratories News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No RDY Message Board. Create One! See More Posts on RDY Message Board See More Message Board Posts

Historical RDY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week72.3972.3970.71571.27200,643-1.12-1.55%
1 Month73.5074.4570.71572.66168,134-2.23-3.03%
3 Months69.7377.7269.2373.83194,2601.542.21%
6 Months67.4577.7263.7269.98225,7673.825.66%
1 Year60.6677.7253.1267.06243,71110.6117.49%
3 Years66.0377.7247.8861.33197,9605.247.94%
5 Years40.5577.7233.3357.10194,35430.7275.76%

Dr Reddys Laboratories Description

Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company's sales are well dispersed across North America, India, and other emerging markets.

Your Recent History

Delayed Upgrade Clock